Managed Care Outlook

U.S. asthma drug costs to jump 50% by 2023


Spending on medications to fight asthma will increase from $16 billion in 2013 to $23 billion in 2023 in the eight countries where most of these drugs are purchased, and one of the main drivers will be new products for severe asthma, according to a study by the consulting company GlobalData.

“The class of fixed-dose combinations (FDCs) of inhaled corticosteroids ... and long-acting beta-agonists ... is the leading drug class in terms of market value,” the study states, “and currently captures almost half of the total asthma market; however, its market share will shrink to 23% as targeted biologics for the treatment of severe asthma enter the market over the forecast period and start dominating the space, growing from 8.7% to 32% of the total asthma sales.”

Providers “will see a clear shift toward personalized medicine for the treatment of severe asthmatics.... It is now clear that severe asthma is not a single disease, but rather, consists of several clinical phenotypes, each having a unique underlying pathological pathway,” the study states.

The researchers add, “The uptake of these novel drugs will be a major driver of the asthma market growth and will offset the dip in sales caused by Singulair’s (montelukast’s) recent patent expiry and the patent expiry of numerous short-acting beta-agonist … products by 2017.”

Asthma: Key Metrics, 2013–2023
2013 epidemiology
Asthma-diagnosed prevalent population 60.6 million
Asthma-treated population 40.5 million
2013 market sales
United States $10.1B
Worldwide $15.9B
Pipeline assessment
Number of drugs in phase 2b–3 8
Number of first-in-class drugs 5
Most promising pipeline drugs Peak-year sales
GlaxoSmithKline’s (GSK’s) fluticasone furoate $1.7B
Sanofi/Regeneron’s dupilumab $1.1B
GSK’s Bosatria (mepolizumab) $863M
Teva’s Cinquil (reslizumab) $863M
Roche’s quilizumab $753M
Key events (2013–2023) Level of impact
Symbicort (budesonide/formoterol fumarate) patent expiration in 2014 ↓ ↓ ↓
Launch of fluticasone furoate in 2015 ↑↑↑
Advair Diskus (fluticasone propionate/salmeterol) patent expiration in 2016 ↓ ↓ ↓
Flovent (fluticasone propionate) patent expiration in 2016 ↓ ↓
Launch of Bosatria in 2016 ↑↑
2023 projected market sales
United States $15.3B
Worldwide $23.1B
Source: Asthma – Global Drug Forecast and Market Analysis to 2023, GlobalData, August 2014